News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
May 31, 2022
Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine CandidateMay 05, 2022
Clover's Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of ConcernApr 27, 2022
Clover Appoints LiongHo Chua as President of Greater ChinaApr 20, 2022
Clover's Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious DiseaseApr 19, 2022
Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washington 2022Mar 29, 2022
Clover Reports Full Year 2021 Financial ResultsMar 17, 2022
Clover's COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a BoosterFeb 24, 2022
Clover Selected for Inclusion on the Hang Seng Composite IndexFeb 14, 2022
Clover Provides Corporate Update and 2022 PrioritiesFeb 01, 2022
Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and Development
